ClinicalTrials.gg
RecruitingNCT07650565hiPSSSUpdated Oct 29, 2026

Tissue Modeling in Systemic Sclerosis Using Induced Pluripotent Stem Cells (iPSCs)

An interventional study of Blood Sample Collection in Systemic Sclerosis (SSc), sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Basic science

How we know

Updated Oct 29, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 132 studies in Scleroderma, Systemic with a site in France — 44 open to participants now, 48 under way, 7 of them phase 3. Scleroderma, Systemic · France.

Planned enrollment
75th of 81
16 · median 75
Started
2026
with 14 others
No phase
35 of 132
8 open now
Primary completion
2028-04
later than 23 of 47 live
Registered
125th of 132
by date
Lead sponsor
5 of 132
University Hospital, Montpellier

Among the 132 studies in Scleroderma, Systemic with a site in France, this one is the 75th largest by planned enrollment of the 81 interventional ones that give a count, is one of 15 that started in 2026, is one of 35 with no phase, reaches primary completion later than 23 of the 47 other live ones, and was the 125th registered.

Scleroderma, Systemic

614 studies on the registry are indexed under Scleroderma, Systemic; 222 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

44 of the 132 studies in Scleroderma, Systemic with a site in France are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 147 Scleroderma, Systemic studies recruiting now, 85 (58%) set no upper age limit and 49 (33%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Scleroderma, Systemic with a site in France, or all of them as a file.
02

Study summary

The objective of the study is to establish an in vitro model using iPSCs to test the hypotheses developed.

The primary objective is to generate, via the SAFE-IPS platform, 8 iPSC lines derived from blood samples taken from:

  • Two patients with severe/diffuse SSc with multi-organ involvement (with anti-SCl-70 autoantibodies)
  • Two of their healthy close relatives
  • Two patients with uncomplicated SSc with localized involvement (with non-SCl-70 autoantibodies)
  • Two of their healthy close relatives

These 8 cell lines will be differentiated by several teams at the FHU REGENHAB into:

  • Immune cells (monocytes/macrophages, neutrophils, dendritic cells, B/T lymphocytes)
  • Mesenchymal stromal cells
  • Myocardial cells
  • Skin cells (fibroblasts)
  • Synovial cells
  • Bronchial cells
  • Endothelial cells

This project aims to map cellular and tissue heterogeneity using iPSC lines obtained from patients with both severe and mild SSc, employing single-cell RNA-seq under various pathological conditions, with and without autologous (or even heterologous) autoimmune stimulation. For example, the percentages of different cell types comprising a tissue in these various situations will be calculated. Comparisons will be made with control groups using healthy iPSC lines by recruiting healthy subjects with the same genetic profile and gender as the patients.

Read the detailed description

Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease that predominantly affects women, often has a severe course, and is characterized by heterogeneous multiorgan involvement. Its pathophysiology, involving microvascular abnormalities, autoimmune activation, and progressive fibrosis, remains incompletely understood, particularly regarding its variations across clinical forms and affected organs. Currently available treatments rely primarily on immunosuppressive strategies, which have limited efficacy and are associated with significant adverse effects, with no therapeutic option available to prevent certain major complications. In this context of unmet medical need, the use of induced pluripotent stem cells (iPSCs) derived from patients with SSc represents an innovative approach to modeling the pathophysiological mechanisms of the disease in vitro. The FHU Regenhab consortium's demonstrated ability to differentiate iPSCs into several relevant cell types offers a unique opportunity to study specific organ damage and identify new therapeutic targets, paving the way for more personalized treatment strategies.

Primary objective:

The primary objective is to generate, using the SAFE-IPS platform, 8 iPSC lines derived from cells obtained from a blood sample from:

  • Two patients with severe/diffuse SSc and multi-organ involvement (with anti-SCl-70 autoantibodies)
  • Two of their healthy close relatives
  • Two patients with uncomplicated SSc with localized involvement (with non-SCl-70 autoantibodies)
  • Two of their healthy close relatives

These 8 cell lines will be differentiated by several teams at the FHU REGENHAB into:

  • Immune cells (monocytes/macrophages, neutrophils, dendritic cells, B/T lymphocytes)
  • Mesenchymal stromal cells
  • Myocardial cells
  • Skin cells (fibroblasts)
  • Synovial cells
  • Bronchial cells
  • Endothelial cells This project aims to map cellular and tissue heterogeneity using iPSC lines by recruiting patients with severe and mild SSc, via single-cell RNA-seq, under various pathological conditions, with and without autologous (or even heterologous) autoimmune stimulation. For example, the percentages of different cell types comprising a tissue in these various situations will be calculated. Comparisons will be made with control groups using healthy iPSC lines by recruiting healthy subjects with the same genetic profile and gender as the patients.

Secondary objectives:

Signaling pathways and major biological processes that are differentially activated and suppressed under various conditions will be analyzed comparatively to better understand the extent to which the addition of the autoantibody alters cellular biology.

The identified signaling pathways will enable pharmacological modulation of differentiated tissue cultures. For example: if the ERK2/3 pathway is more active in differentiated tissues obtained from SSc patients compared to controls, as reported in Kim's publication (SCRT 2022), pharmacological modulation will be tested with and without the addition of autoantibodies. The tissue phenotype will be recharacterized using immunohistochemistry, conventional biochemistry for protein expression, and transcriptomic analysis.

A maximum of 8 patients will be enrolled, with the aim of having at least two evaluable patients per group: two patients with severe/diffuse SSc and two patients with localized/uncomplicated SSc. Enrollment will be halted once two iPSC lines differentiated into at least one target cell type have been obtained for each condition.

Investigators will simultaneously include healthy subjects without autoimmune diseases matched to each patient (n=8 maximum).

03

Conditions studied

  • Systemic Sclerosis (SSc)

Keywords

  • Systemic Sclerosis
  • Induced Pluripotent Stem Cells
  • Autoimmune Disease
  • Tissue Modeling
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 85 years
  • Diagnostic criteria for the three groups:

    > Severe SSc group:

  • Diagnosis of diffuse/severe systemic sclerosis by a physician for at least 12 months based on recommendations (according to ACR criteria)
  • Known positivity of autoimmunity directed against Scl-70

    > Localized/non-complicated SSc group:

  • Diagnosis of systemic sclerosis by a physician for at least 12 months based on recommendations (according to ACR criteria)
  • Documentation of the absence of major vital organ involvement
  • Negative anti-Scl-70 autoantibodies but presence of other systemic sclerosis-related autoantibodies

    > Healthy subjects group:

  • First-degree relative of a patient recruited in one of the systemic sclerosis groups (father, mother, brother, sister, adult child)
  • Absence of systemic diseases

Exclusion criteria

Exclusion Criteria:

  • Other diseases that may affect erythroid progenitor cells (non-exhaustive: active cancer, hematological , chemotherapy targeting DNA)
  • Patient in an exclusion period determined by another protocol
  • Protected populations according to French public health law (pregnant or breastfeeding women; individuals deprived of liberty by judicial or administrative decision; adults under legal protection (any form of guardianship))
  • Absence of
  • Not affiliated with a national health insurance system
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Participants with Systemic Sclerosis and Healthy Controls

    Participants undergo blood sample collection for generation of induced pluripotent stem cells (iPSCs) and in vitro cellular and tissue modeling.

    Procedure: Blood Sample Collection

Interventions

  • ProcedureBlood Sample Collection

    Collection of approximately 28 mL of blood from each participant to generate induced pluripotent stem cell (iPSC) lines for in vitro cellular and tissue modeling analyses.

06

What researchers measure

Primary outcomes

  1. Rate of successful iPSC line generation from PBMCs in diffuse/severe systemic sclerosis patients

    Percentage of participants with diffuse/severe systemic sclerosis (anti-Scl-70 positive) from whom at least one iPSC line is successfully generated via Sendai virus reprogramming of peripheral blood mononuclear cells (PBMCs). Unit of Measure: % of participants with at least one validated iPSC line

    Time frame: At inclusion (Day 0 blood draw; iPSC generation assessed within approximately 3 months post-collection)

  2. Rate of successful differentiation of iPSCs into at least one target functional cell type in localized/non-complicated systemic sclerosis patients

    Among validated iPSC lines from localized/non-complicated SSc patients, the percentage of lines achieving successful directed differentiation into at least one target cell type (cardiomyocytes, macrophages, bronchial epithelial cells, immune cells, or fibroblasts). Success is confirmed by cell-type-specific marker expression assessed by immunofluorescence and flow cytometry. Unit of Measure: % of validated iPSC lines successfully differentiated into ≥1 target cell type

    Time frame: At inclusion (assessed within approximately 6 months post-collection)

  3. Rate of successful iPSC line generation from PBMCs in localized/non-complicated systemic sclerosis patients

    Percentage of participants with localized/non-complicated systemic sclerosis (anti-Scl-70 negative, other SSc-specific antibody positive) from whom at least one iPSC line is successfully generated via Sendai virus reprogramming of PBMCs. Unit of Measure: % of participants with at least one validated iPSC line

    Time frame: At inclusion (Day 0 blood draw; iPSC generation assessed within approximately 3 months post-collection)

  4. Rate of successful differentiation of iPSCs into at least one target functional cell type in diffuse/severe systemic sclerosis patients

    Among validated iPSC lines from diffuse/severe SSc patients, the percentage of lines achieving successful directed differentiation into at least one target cell type (cardiomyocytes, macrophages, bronchial epithelial cells, immune cells, or fibroblasts). Success is confirmed by cell-type-specific marker expression assessed by immunofluorescence and flow cytometry (e.g., cTnT for cardiomyocytes; CD68/CSFR1 for macrophages; NKX2.1/MUC5AC for bronchial epithelium). Unit of Measure: % of validated iPSC lines successfully differentiated into ≥1 target cell type

    Time frame: At inclusion (assessed within approximately 6 months post-collection)

Secondary outcomes

  1. Change in cardiomyocyte differentiation efficiency following autologous autoantibody exposure

    Comparison of ventricular cardiomyocyte differentiation efficiency, expressed as percentage of cardiac troponin T-positive (cTnT+) cells by flow cytometry, in iPSC-derived cardiomyocytes cultured with vs. without addition of autologous serum containing patient-specific autoantibodies. Serum is collected at Day 0 blood draw and stored at -80°C until use. Unit of Measure: % cTnT-positive cells (flow cytometry) - with vs. without autologous serum

    Time frame: At inclusion

  2. Change in macrophage differentiation and inflammatory cytokine secretion following autologous autoantibody exposure

    Assessment of iPSC-derived macrophage phenotype (% CD68+, CSFR1+, CD163+ cells by flow cytometry) and inflammatory response (secretion of CCL2, IL-6, CXCL1, CXCL8 measured by ELISA in pg/mL) under baseline conditions and following addition of autologous autoantibody-containing serum, compared between SSc patient-derived and healthy control-derived macrophages. Unit of Measure: Cytokine concentration (pg/mL) by ELISA; % CD68+/CSFR1+ cells by flow cytometry

    Time frame: At inclusion

  3. Functional characterization of iPSC-derived cardiomyocytes - spontaneous beating activity

    Proportion of iPSC-derived ventricular cardiomyocyte clusters exhibiting spontaneous contractile activity, assessed by video microscopy, as a measure of functional maturation following 2D differentiation and 3D spheroid formation using Matrigel. Maturation is further assessed after small molecule treatment with triiodothyronine (T3) and lipid-soluble cyclic AMP. Unit of Measure: % spontaneously beating clusters (video microscopy)

    Time frame: At inclusion

  4. Molecular characterization of iPSC-derived cardiomyocytes - cardiac marker expression

    Assessment of cardiomyocyte identity by flow cytometry (% cardiac troponin T-positive cells) and RT-qPCR quantification of cardiac-specific genes (MYH6, MYH7, TNNI3, KCNH2) in iPSC-derived cardiomyocytes from SSc patients compared to healthy matched controls. Unit of Measure: % cTnT-positive cells (flow cytometry); relative gene expression (RT-qPCR, arbitrary units normalized to housekeeping gene)

    Time frame: At inclusion

  5. Phenotypic characterization of iPSC-derived macrophages - pan-macrophage surface marker expression

    Quantification of pan-macrophage surface marker expression (CD68, CSFR1, CD163) by flow cytometry in iPSC-derived macrophages (iMACs) generated via embryoid body-based xeno-free protocol. Pluripotency gene silencing is confirmed by RT-qPCR (SOX2, NANOG, OCT4 downregulation relative to parental iPSCs). Unit of Measure: % CD68+, % CSFR1+, % CD163+ cells (flow cytometry)

    Time frame: At inclusion

  6. Transcriptomic characterization of iPSC-derived macrophages - inflammatory gene regulation

    Single-cell RNA sequencing-based characterization of iPSC-derived macrophage transcriptional programs, including quantification of pro-inflammatory gene expression (CCL2, CCL8, FASN, LPIN1, IL-6) under baseline and autoantibody-stimulated conditions. Transcriptomic profiles are compared between SSc patient-derived and healthy control-derived iMAC lines. Unit of Measure: Normalized gene expression counts (single-cell RNA sequencing, scRNA-seq)

    Time frame: At inclusion

  7. Characterization of iPSC-derived immune cells - antigen-presenting cell differentiation efficiency

    Assessment of iPSC differentiation efficiency toward antigen-presenting cell lineages (dendritic cells and B/T lymphocyte precursors) using FLT3 overexpression-based differentiation protocol. Differentiation efficiency is quantified by flow cytometry using lineage-specific surface markers. Unit of Measure: % FLT3L-responsive antigen-presenting cell progenitors (flow cytometry)

    Time frame: At inclusion

  8. Characterization of iPSC-derived bronchial epithelial cells - stepwise differentiation efficiency

    Stepwise quantification of bronchial epithelial differentiation efficiency by immunofluorescence at three sequential stages: (1) definitive endoderm: % CXCR4+/SOX17+/FOXA2+ cells; (2) bronchial progenitor stage: % NKX2.1+ cells negative for thyroid marker TG and forebrain marker FOXG1; (3) final air-liquid interface epithelium (iALI): % mucus-secreting cells (MUC5AC+) and % ciliated cells (acetylated alpha-tubulin+). Unit of Measure: % CXCR4+/SOX17+/FOXA2+ cells at endoderm stage; % NKX2.1+/TG-/FOXG1- cells at progenitor stage; % MUC5AC+ and % acetylated alpha-tubulin+ cells at final iALI stage (immunofluorescence)

    Time frame: At inclusion

  9. Functional characterization of iPSC-derived bronchial air-liquid interface epithelium (iALI) - barrier integrity and mucociliary function

    Functional assessment of iPSC-derived air-liquid interface bronchial epithelium (iALI) obtained after 4-6 weeks of directed differentiation. Epithelial barrier integrity is quantified by transepithelial electrical resistance (TEER, ohm·cm²) on Transwell inserts. Mucociliary function is assessed by ciliary beat frequency measured by high-speed video microscopy (Hz). Results are compared between SSc patient-derived and healthy control-derived iALI cultures. Unit of Measure: Transepithelial electrical resistance (TEER, ohm·cm²); ciliary beat frequency (Hz, video microscopy)

    Time frame: At inclusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Apr 2028, 18 months after the start.

Of 95 non-industry interventional studies with no phase under Scleroderma, Systemic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 18 months is below that.

Counting every sponsor, half of 101 studies reached it within 23 months; a quarter within 10 and three quarters within 38.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: start Sep 2026 → Oct 2026, primary completion Mar 2028 → Apr 2028 and completion Mar 2028 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2026
First posted
Jun 16, 2026
StartActual
Oct 27, 2026was Sep 2026
Primary completionEst.
Apr 2028was Mar 2028
CompletionEst.
Apr 2028was Mar 2028
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 29, 2026
Sites
University hospital Montpellier is now Recruiting
Oct 29, 2026
Start date
Sep 2026→Oct 27, 2026 (actual)
Oct 29, 2026
Primary completion
Mar 2028→Apr 2028
Oct 29, 2026
Study completion
Mar 2028→Apr 2028
Oct 29, 2026
Secondary outcomes
2 description edited
What changed in the outcomes
  • DescriptionCharacterization of iPSC-derived immune cells - antigen-presenting cell differentiation efficiency: how it is measured was reworded
  • DescriptionPhenotypic characterization of iPSC-derived macrophages - pan-macrophage surface marker expression: how it is measured was reworded
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Not yet recruiting→Recruiting
    University hospital Montpellier is now Recruiting
    Start date Sep 2026→Oct 27, 2026 (now actual)
    Primary completion Mar 2028→Apr 2028
    Study completion Mar 2028→Apr 2028
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionCharacterization of iPSC-derived immune cells - antigen-presenting cell differentiation efficiency: how it is measured was reworded
    • DescriptionPhenotypic characterization of iPSC-derived macrophages - pan-macrophage surface marker expression: how it is measured was reworded
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07650565
Responsible party
Sponsor
First posted
Jun 16, 2026
Start date
Oct 27, 2026
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Oct 29, 2026

Study contacts

ARNAUD BOURDIN, MD
Contact
a-bourdin@chu-montpellier.fr
04 67 33 61 26
ARNAUD BOURDIN, MD
study director · University Hospital, Montpellier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion